These correctly-folded proteins are selected from a recent seminal scientific publication that reviewed and compiled all proteins that are implicated in mediating cancer
Sigma-Aldrich announces the launch of Panorama Human Cancer Version 1 protein functional microarray.
Developed by Procognia, and licensed exclusively through Sigma-Aldrich, the Cancer V1 protein microarray contains 130 correctly folded proteins.
These proteins are selected from a recent seminal scientific publication that reviewed and compiled all proteins that are implicated in mediating cancer.
"The field of oncology research has benefited greatly from the post-genome era, however, the characterisation of genes alone does not reflect the full dynamics of cellular activity.
"This level of investigation needs to be conducted at the proteomic level," commented Michael Hadjisavas, global marketing manager of proteomics at Sigma-Aldrich.
"Given the complex nature of proteins and their critical role in cancer expression, our focus is to support cancer research at the proteomic level.
"By utilising a proprietary immobilisation technology that allows proteins to be correctly folded, uniformly orientated, and stearically unencumbered, the analysis of protein function and interactions involved in the cancer process that have physiological relevance can be confidently identified".
The Panorama Human Cancer V1 protein functional microarray is a new addition to the Sigma-Aldrich microarray product line.
This product extends Sigma's array portfolio for proteomics research including arrays of proteins, antibodies, peptides and tissue extracts.
Sigma-Aldrich is a life science and high technology company.
The company's biochemical and organic chemical products and kits are used in scientific and genomic research, biotechnology, pharmaceutical development, the diagnosis of disease and as key components in pharmaceutical and other high technology manufacturing.
It has customers in life science companies, university and government institutions, hospitals, and in industry.
Over one million scientists and technologists use its products.
Sigma-Aldrich operates in 35 countries and has over 6800 employees.
Procognia, a 2004 World Economic Forum Technology Pioneer award winner, is focused on developing and commercialising its cutting edge proprietary technologies that will enable the unravelling of disease mechanisms and the discovery and development of drugs to treat those diseases.
In addition to developing protein function arrays, Procognia has also developed and is marketing a lectin array based platform that enables the high throughput, automated analysis of protein glycosylation.
Glycosylation is the major post-translational modification of protein drugs, and it is the most difficult aspect to analyse, monitor and control during the discovery and development of biologic medicines.
Procognia says its glycanalysis technology will increase the probability of success of glycoprotein drugs.
